Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
NCT ID: NCT03087786
Last Updated: 2021-01-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
100 participants
INTERVENTIONAL
2017-03-21
2017-08-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation
NCT00985985
Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations
NCT01574898
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
NCT02688374
Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations
NCT01847443
4 mg Nicotine Polacrilex Gum and Swedish Portion Snus
NCT01182129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To evaluate the safety and tolerability of Nicotine Bitartrate 4 mg mint lozenge and Nicorette® \[Nicotine Polacrilex\] 4 mg mint lozenge in this subject population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotine Bitartrate 4mg Lozenge
Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
Nicotine Bitartrate Lozenge 4mg
Test Product
Nicotine Polacrilex 4mg Lozenge
Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
Nicotine Polacrilex 4Mg Lozenge
Active Comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotine Bitartrate Lozenge 4mg
Test Product
Nicotine Polacrilex 4Mg Lozenge
Active Comparator
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Sex and Age: Males and females aged at least 18 years and older.
2. Informed of the nature of the study and have agreed to and are able to read, review, and sign the informed consent document prior to commencing any study specific procedures. The informed consent document will be written in English, therefore the volunteer must have the ability to read and communicate in English.
3. Must have smoked at least 10 cigarettes per day for the previous 12 months prior to screening.
4. Must smoke first cigarette within 30 minutes of waking up.
5. Must be motivated to quit smoking upon enrollment into the study.
6. Contraception: Females of childbearing potential who have been, in the opinion of the Investigator, practicing a reliable method of contraception for at least two months prior to study participation and must agree to remain on an acceptable method of contraception while participating in the study period using the study medication. Acceptable methods of contraception are hormonal birth control, intrauterine device, double barrier methods, vasectomized partner or abstinence.
7. Females of childbearing potential will be required to undergo a serum (Screening) and urine (Day 0) pregnancy test (must be negative).
8. Females of non-childbearing potential must be surgically sterile for at least three months prior to Screening or post-menopausal for at least two years.
9. General health: All study participants must have good general health and no impairment that would impede or affect ability to participate in the study as deemed acceptable by the Investigator.
10. Compliance: All study participants must understand and be willing to comply with all study procedures and restrictions.
11. Consent: All study participants must demonstrate willingness to participate as evidenced by voluntary written informed consent and must have received a signed and dated copy of the informed consent form.
Exclusion Criteria
2. Nicotine use:
1. Is unable/unwilling to stop using forms of tobacco (e.g., traditional cigarettes, chewing tobacco, nicotine gels, cigars, snuff tobacco, nicotine patch and electronic cigarettes) for the duration of the study.
2. Is unable/unwilling to stop using other nicotine replacement therapy products throughout the duration of the study.
3. Disease: Has a medical history, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results, e.g., known history of heart disease, recent myocardial infarction or cerebrovascular accident (i.e., within 12 weeks prior to enrollment), unstable angina, severe cardiac arrhythmia, diabetes or peptic ulcer.
4. Demonstrates a reactive screen for Hepatitis B surface antigens, hepatitis C antibody, or HIV antibody.
5. Oral condition:
1. Has history of oral surgery (including extractions) within four weeks of screening, operative dental work within seven days of screening, or a presence of any clinically significant oral pathology (as determined by an oral health professional - dentist or dental hygienist) including lesions, sores or inflammation of the mouth which would interfere with study assessments or confound the results.
2. Has fixed retainers, orthodontic appliances, or either maxillary and/or mandibular dentures or other appliances which may interfere with the placement of the product.
3. Has current or recurrent disease that could affect the site of application, the action, absorption of the study treatment, or clinical assessment.
4. Has severe gingivitis, periodontitis or rampant caries (extensive dental decay, i.e., big/deep cavities, in many teeth), as diagnosed by an oral health professional- dentist or dental hygienist.
5. Has the presence of oral or peri-oral ulceration including herpetic lesions at screening (subjects with these lesions may be re-examined at a subsequent appointment and may be able to be admitted at a later date if the ulceration or herpetic lesion heals) or Study Visit Day 0.
6. Has elective dentistry scheduled during the study duration.
6. Allergy/Intolerance:
1. Has a known or suspected intolerance or hypersensitivity to the study materials (or closely-related compounds) or any of their stated ingredients.
2. Has a known genetic deficiency with an inability to metabolize aspartame or phenylalanine or has been diagnosed with phenylketonuria.
7. Clinical Study Participation:
1. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit at the start of the study.
2. Previous participation in this study.
8. Substance abuse:
1. Current or recent (within two years of screening) history of drug or alcohol abuse, misuse, physical or psychological dependence.
2. Demonstrates a positive alcohol breath test.
3. Demonstrates a positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s) at Screening and Study Visit Day 0.
9. Urine glucose:
a) Positive glucose urine screen.
10. Personnel:
1. Is an employee of the Sponsor or the study site.
2. Is a member of the same household as another subject in this trial.
11. Use of all over the counter (OTC) and prescription (Rx) lozenges after starting the study (Day 0 and onward).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inflamax Research Incorporated
INDUSTRY
Niconovum USA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frank Lee, MD, CPI
Role: PRINCIPAL_INVESTIGATOR
Inflamax Research Incorporated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inflamax Research Inc
Newark, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-NBTL-S-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.